Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Acerus has commercialized Natesto®—a bioadhesive intranasal testosterone gel for male hypogonadism—and Estrace®, an oral plant-derived estradiol therapy for menopausal symptoms. Gynoflor® offers ultra-low dose vaginal estrogen therapy. Noctiva™—a vasopressin analog nasal spray—is approved in the US for nocturia. Tefina®, a low-dose nasal testosterone gel for female sexual dysfunction and Lidbree™, a short acting lidocaine formulation delivered intravaginally are in development. The company’s pipeline also includes combination therapies targeting benign prostatic hyperplasia and overactive bladder[1][3][6][8].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Acerus Pharmaceuticals.